Intensive Local Therapy to Renal Cell Carcinoma Bone Metastases May Increase Survival

Share this content:
Intensive local therapy to bone lesions in patients with renal cell carcinoma with bone metastases may improve survival.
Intensive local therapy to bone lesions in patients with renal cell carcinoma with bone metastases may improve survival.

NEW ORLEANS—Intensive local therapy to bone lesions in patients with renal cell carcinoma (RCC) with bone metastases may improve survival, data presented at the 2015 American Urological Association annual meeting.

The data are from a retrospective Japanese study of 70 RCC patients with bone metastases (BM). Of these, 27 (39%) had multiple BM. BM sites included the vertebra (38 patients), pelvis (18 patients), long bones (21 patients), and other sites (23 patients).

For the study, Hiroshi Fukushima, MD, and colleagues at Tokyo Metropolitan Cancer and Infectious Diseases Center, defined intensive local therapy as surgical resection with a wide margin or radiotherapy with a biologically effective dose of 140 Gy or greater to BM.

The investigators classified patients into 3 groups: intensive local therapy to BM with curative intent to the other lesions (level 1, 19 patients); intensive local therapy to BM without curative intent to the other lesions (level 2, 15 patients); and less intensive or no local therapy (level 3, 36 patients).

RELATED: Metastasectomy May Raise Survival in Metastatic Renal Cell Carcinoma

During a median follow-up of 13 months, 37 patients (53%) died. The median overall survival rate was 22 months. 

Patients in level 1, 2, and 3 had 1-year overall survival rates of 84%, 70%, and 51%, respectively. On multivariate analysis, intensive local therapy to BM independently predicted a significant 55% decreased risk of death compared with less intensive or no local therapy.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs